ReviewKorean circulation journal2019
Ideal Target Blood Pressure in Hypertension.
Review in Korean circulation journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force.Annals of the rheumatic diseases · 2023Pooled it
- Effectiveness of an amlodipine and perindopril arginine-based strategy for hypertension management in Morocco: a prospective observational study.The Pan African medical journal · 2025Observational
- Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force.Clinical immunology (Orlando, Fla.) · 2024Article
- Vasodilation and Blood Pressure-Lowering Effect of 3-Demethyl-2-Geranyl-4-Prenylbellidifoline, a Xanthone Obtained fromPlants (Basel, Switzerland) · 2024Article
- Predicting factors of blood pressure normalization in hypertensive patients after short-term follow-up.Frontiers in cardiovascular medicine · 2024Article
- Sex differences in the applicability of Western cardiovascular disease risk prediction equations in the Asian population.PloS one · 2024Article
- PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS).Clinical immunology (Orlando, Fla.) · 2023Article
- Angiotensin converting enzyme (ACE) inhibitors activity from purified compounds Fructus Phaleria macrocarpa (Scheff) Boerl.BMC complementary medicine and therapies · 2023Article
- Predicting the risk of hypertension using machine learning algorithms: A cross sectional study in Ethiopia.PloS one · 2023Article
- Long-term cardiovascular events in hypertensive patients: full report of the Korean Hypertension Cohort.The Korean journal of internal medicine · 2023Article
- The association of lipid-lowering therapy and blood pressure control among outpatients with hypertension at the Felege Hiwot Comprehensive Specialized Hospital, Northwest Ethiopia.Frontiers in cardiovascular medicine · 2023Article
- Cost-effectiveness analysis of intensive blood pressure control in Korea.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment.Frontiers in cardiovascular medicine · 2022Review
- Suboptimal Management Status of Younger Hypertensive Population in Korea.Korean circulation journal · 2021Article
- An Open-label, Single-arm, Multicenter Feasibility Study Evaluating the Safety of Catheter-based Renal Denervation with DENEX™ in Patients with Uncontrolled Hypertension on Standard Medical Therapy.Korean circulation journal · 2021Article
- Role of self-care in COVID-19 pandemic for people living with comorbidities of diabetes and hypertension.Journal of family medicine and primary care · 2020Review
- Effects of Cardiovascular Risk Factor Variability on Health Outcomes.Endocrinology and metabolism (Seoul, Korea) · 2020Review
- Reassembling Evidence for Treatment in Asymptomatic Carotid Artery Stenosis.Korean circulation journal · 2020Article
- Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.Biological procedures online · 2020Article
- Big Challenge in Big Data Research: Continual Dispute on Big Data Analysis.Korean circulation journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive blood pressure (BP) lowering was associated with significant reduction in composite cardiovascular (CV) outcomes in hypertension. Subsequently, several meta-analyses have corroborated the findings from SPRINT and these benefits were more prominent in subjects with higher cardiovascular risk at baseline. As such, the recent American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and the European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guideline recommended the lowering of target BP to less than 130/80 mmHg in most hypertensive subjects. However, one should keep in mind the potential harm of too much BP lowering. Post hoc analysis of clinical trials have demonstrated increased cardiovascular mortality and events with too much BP lowering. Therefore, although intensive BP lowering may be beneficial in further reducing CV outcomes, too much reduction below 120/70 mmHg may actually harmful. In conclusion, although intensive BP lowering to achieve target BP below 130/80 mmHg is beneficial in reducing CV outcomes, one should do so cautiously as to avoid adverse events. As such, the first target of anti-hypertensive treatment should be to achieve BP lowering below 140/90 mmHg. Once that target is achieved, one could target BP below 130/80 mmHg keeping in mind to avoid signs of organ hypoperfusion such as orthostatic hypotension, orthostatic dizziness, weakness and serum creatinine elevation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.